NATHAN PLATT: Open Payments
NPI 1003450057 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$853 in 42 payments from 7 companies in 2025. Trend: 2023 $561 · 2024 $474 · 2025 $853
Food & beverage: $853
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 12 | $210 |
| Novo Nordisk Inc | 11 | $201 |
| ABBVIE INC. | 7 | $178 |
| AstraZeneca Pharmaceuticals LP | 6 | $119 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| Eisai Inc. | 2 | $55 |
| GlaxoSmithKline, LLC. | 1 | $35 |
Products named: VRAYLAR, MOUNJARO, Wegovy, CAPLYTA, Leqembi, AIRSUPRA, FARXIGA, TRELEGY ELLIPTA.
Industry payments across PA — which companies pay providers there.
